LBPO.MCB01 · 分子与细胞生物学 · Late-Breaking
全基因组测序揭示子宫内膜癌各亚型间不同的突变机制
Whole-genome sequencing reveals distinct mutational mechanisms across endometrial cancer subtypes
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
子宫体子宫内膜癌(UCEC)是全球最常见的妇科恶性肿瘤之一,并且是一个日益加重的公共卫生负担,尤其是在高收入国家。尽管临床管理取得了进展,UCEC的死亡率仍在持续上升,并存在显著的种族和社会经济差异。癌症基因组图谱(TCGA)此前建立了一个分子框架,将UCEC分类为四种主要亚型:POLE超突变型、微卫星不稳定性高(MSI)型、拷贝数低(CN-Low)型和拷贝数高(CN-High)型。然而,缺乏全基因组测序(WGS)限制了对UCEC基因组结构的全面表征。在此,我们分析了440例TCGA UCEC肿瘤的WGS数据,并结合配对的多组学数据,以系统地表征亚型特异性突变过程、结构变异及其临床关联。在驱动基因中,POLE超突变型肿瘤表现出广泛的多重突变、移码插入缺失减少以及亚克隆异质性增加。在整个UCEC中,LINE-1逆转录转座事件主要起源于chr22q12.1的种系来源,其中子宫内膜样CN-High肿瘤显示出最高水平的转座元件活性。CN-High肿瘤还表现出高频率的染色体外DNA(ecDNA)扩增,以MYC-PVT1和ERBB2-MIEN1位点的共扩增为主,而ecDNA事件在其他亚型中罕见。在CN-High肿瘤中,LINE-1插入负荷与ecDNA形成密切相关,提示逆转录转座相关的基因组不稳定与通过ecDNA的癌基因扩增之间存在机制联系。相比之下,浆液样CN-Low肿瘤的特征是较高的患者体重指数(BMI)、较低的复制应激和增加的X染色体失活。突变特征分析揭示了显著的亚型特异性。APOBEC特征在很大程度上局限于CN-High肿瘤。SBS39是一种此前未被表征的特征,在CN-High肿瘤中高度普遍,并与BMI显著相关。MSI肿瘤表现出一种新的DBS特征,富含含A/T的反向双碱基替换(XY→YX),而插入缺失突变几乎无处不在,并局限于ID1和ID2特征。值得注意的是,MSI肿瘤中的ID2与ID1比值比非MSI肿瘤高约十倍,表明存在与错配修复缺陷相关的模板链复制滑移的强烈偏向。总之,这些发现揭示了UCEC中此前未被认识的亚型特异性基因组特征,并定义了不同的突变机制,对精细化的风险分层和治疗策略具有潜在意义。
查看英文原文 English abstract
Uterine corpus endometrial carcinoma (UCEC) is among the most prevalent gynecologic malignancies worldwide and represents a growing public health burden, particularly in high-income countries. Despite advances in clinical management, UCEC mortality continues to rise, with marked racial and socioeconomic disparities. The Cancer Genome Atlas (TCGA) previously established a molecular framework classifying UCEC into four major subtypes: POLE-ultramutated, microsatellite instability-high (MSI), copy-number low (CN-Low), and copy-number high (CN-High). However, the lack of whole-genome sequencing (WGS) has limited comprehensive characterization of UCEC genomic architecture. Here, we analyzed WGS data from 440 TCGA UCEC tumors, together with matched multi-omics data, to systematically characterize subtype-specific mutational processes, structural variation, and their clinical associations. Among driver genes, POLE-ultramutated tumors exhibited extensive multiple mutations, depleted frameshift indels, and increased subclonal heterogeneity. Across UCEC, LINE-1 retrotransposition events predominantly originated from a germline source at chr22q12.1, with endometrioid-like CN-High tumors displaying the highest level of transposable element activity. CN-High tumors also showed high frequent extrachromosomal DNA (ecDNA) amplification, dominated by co-amplification of the MYC - PVT1 and ERBB2 - MIEN1 loci, whereas ecDNA events were rare in other subtypes. Within CN-High tumors, LINE-1 insertion burden was strongly correlated with ecDNA formation, suggesting a mechanistic link between retrotransposition-associated genomic instability and oncogene amplification via ecDNA. In contrast, serous-like CN-Low tumors were characterized by higher patient body mass index (BMI), lower replication stress and increased X-chromosome inactivation. Mutational signature analysis revealed striking subtype specificity. APOBEC signatures were largely restricted to CN-High tumors. SBS39, a previously uncharacterized signature, was highly prevalent in CN-High tumors and significantly associated with BMI. MSI tumors exhibited a novel DBS signature enriched for A/T-containing reversed doublet substitutions (XY→YX), while indel mutagenesis was nearly ubiquitous and restricted to ID1 and ID2 signatures. Notably, the ID2-to-ID1 ratio in MSI tumors was approximately ten-fold higher than in non-MSI tumors, indicating a strong bias toward template-strand replication slippage associated with mismatch repair deficiency. Together, these findings uncover previously unrecognized, subtype-specific genomic features in UCEC and define distinct mutational mechanisms with potential implications for refined risk stratification and therapeutic strategies.
利益披露 Disclosure
J. Sang, None..
M. Zhang, None..
T. Veith, None..
Y. Kim, None..
S. Chavez, None..
W. Zhou, None..
W. Luo, None..
A. Miranda, None..
J. Luebeck, None..
V. Bafna, None..
S. J. Chanock, None..
T. Zhang, None.